GlaxoSmithKline sets up world-class facility

GlaxoSmithKline (GSK) enhanced its investment in Sri Lanka with the setting up of a world-class facility to manufacture Panadol tablets, company sources said.

This investment, amounting to Rs 217 m is one of the largest investments in the Sri Lanka pharmaceutical industry. GSK's parent company continues to have confidence in the country and recently infused a FDI of $ 11.2 m and continues to invest more, he said.

GSK will inaugurate two new state-of-the-art manufacturing facilities to produce Iodex and Eno locally with an investment of Rs 200 m in the first quarter of 2013. GSK in the past two years has brought in major investments to upgrade packaging of Panadol tablets, Horlicks, Viva and manufacturing of Panadol syrup.

GSK a world's largest research based pharmaceutical and Healthcare companies operating in 117 countries has been operating in Sri Lanka since 1958.

- LF